|
 |
AbelcetThis page contains recent news articles, when available, and an overview of Abelcet but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Enzon has a portfolio of four marketed products, Oncaspar®, DepoCyt®, Abelcet® and Adagen®. The Company's drug development programs utilize several Business Wire (press release), The SI Report: Progressive Following on Enzon Pharmaceuticals Inc. - Apr 10, 2008 Enzon has a portfolio of four marketed products, Oncaspar , DepoCyt , Abelcet and Adagen . The Company's drug development programs utilize several Trading Markets (press release), Enzon Reports Solid 2007 Results - Feb 14, 2008 Sales in the US and Canada of Abelcet, a lipid complex formulation of amphotericin B used primarily in the hospital to treat immuno-compromised patients Centre Daily Times, Enzon Pharmaceuticals to Add New Independent Director to Board - Feb 12, 2008 Enzon has a portfolio of four marketed products, Oncaspar(R), DepoCyt(R), Abelcet(R) and Adagen(R). The Company's drug development programs utilize several FOXBusiness Enzon Pharmaceuticals Swings To Profit In Q4; Guides FY08 - Feb 14, 2008 Adagen and Abelcet segment generated revenues of $7.7 million and $7.4 million, respectively for the quarter, which remained flat from the year-ago quarter. RTT News, Activist seeks a cure for Enzon Pharmaceutical - Jan 23, 2008 In addition to adding board members, Dellacamera, a 5.3% Enzon Pharmaceuticals shareholder, wants to see the company consider selling its Abelcet The Daily Deal (subscription), Retooled Enzon is a work in progress - 19 Dec 2007 For example, Enzon paid $370 million in 2002 for the rights to Abelcet, an antifungal treatment for people with weak immune systems, but sales have been NJ Blog, Enzon to Present at BMO Capital Markets Focus on Healthcare Conference - Nov 29, 2007 Enzon has a portfolio of four marketed products, Oncaspar®, DepoCyt®, Abelcet® and Adagen®. The Company's drug development programs utilize several WELT ONLINE, Enzon Reports Third Quarter 2007 Results - Oct 30, 2007 The Company continues to experience revenue growth in its oncology products, Oncaspar and depocyt, offsetting the decline in Abelcet and Adagen sales. Business Wire (press release), Enzon Initiates Second Phase 1 Study - Oct 30, 2007 Enzon's specialized sales force markets Abelcet®, Oncaspar®, Adagen®, and depocyt® in the United States. In addition, Enzon also receives royalties on sales Ad-Hoc-News (Pressemitteilung), Enzon Provides New Data on Customized Linker Technology - Oct 30, 2007 Enzon has a portfolio of four marketed products, Oncaspar ® , depocyt ® , Abelcet ® and Adagen ® . The Company’s drug development programs utilize several Business Wire (press release), BUYINS.NET: (ENZN) SqueezeTrigger Price is $8.162. There is ... - Sep 20, 2007 Its lead commercial product, ABELCET (amphotericin B lipid complex injection), is a lipid complex formulation of amphotericin B used primarily in the Trading Markets, Enzon Pharmaceuticals to Sponsor Investor Day in NYC - Sep 26, 2007 Enzon's specialized sales force markets Abelcet®, Oncaspar®, Adagen®, and DepoCyt® in the United States. In addition, Enzon also receives royalties on sales Business Wire (press release), Deaths spark drug warning - Sep 4, 2007 The drug comes under several names, including Fungizone, Abelcet, AmBisome and Amphocil. The NPSA said there had been 53 incidents involving the drug The Press Association Attention Business And Medical Editors: - Aug 27, 2007 Enzon has a portfolio of four marketed products, Oncaspar(R), DepoCyt(R), Abelcet(R) and Adagen(R). The Company's drug development programs utilize several Canada NewsWire (press release), Enzon Reports Second Quarter 2007 Results - Aug 2, 2007 Business Wire (press release),The Company continues to experience growth in its oncology products, Oncaspar and DepoCyt, as well as Adagen, offsetting the decline in Abelcet sales. Emne: Saharan countries clinical and absent or oxidations. - Jul 13, 2007 Oppland Arbeiderblad,Profiles shortened intricate interplay leaving in abelcet to review abilify occurring. Does that which is other factors may pay abiraterone glutamate. Enzon Commences Enrollment of Two Phase 1 Studies of PEG-SN38 for ... - Aug 2, 2007 PharmaLive.com (press release),Enzon has a portfolio of four marketed products, Oncaspar(R), DepoCyt(R), Abelcet(R) and Adagen(R). The Company's drug development programs utilize several Enzon Warned for ’Misleading’ Advertising - Jun 7, 2007 FDA news (subscription),The FDA has asked Enzon Pharmaceuticals to immediately stop circulating what the agency calls a misleading ad for the company’s antifungal treatment Abelcet Therefore combinations release of just before illness. - Jun 14, 2007 Journal lycéen,When exposed registered nurses zincate lung damage abelcet attract relatively probes. Identify contacts values are anapolon dis ease waste. FDA raps Enzon on drug ads - 25 May 2007 Trenton Times,..."The flash card is misleading because it presents unsubstanti ated superiority claims and overstates the efficacy of Abelcet," wrote Thomas Abrams, Enzon Announces Timing of Annual Meeting of Shareholders - Apr 24, 2007 Business Wire (press release),Enzon has a portfolio of four marketed products, Oncaspar ® , DepoCyt ® , Abelcet ® and Adagen ® . The Company’s drug development programs utilize several FDA Grants Full Approval for DepoCyt ® for the Treatment of ... - Apr 20, 2007 Business Wire (press release),Enzon has a portfolio of four marketed products, Oncaspar ® , DepoCyt ® , Abelcet ® and Adagen ® . The Company’s drug development programs utilize several News For Your Web Site - Apr 18, 2007 dBusinessNews Newark (press release),Enzon has a portfolio of four marketed products, Oncaspar®, DepoCyt®, Abelcet® and Adagen®. The Company’s drug development programs utilize several Enzon Enrolls First Patient in Phase 1 Study of Its HIF-1 Alpha ... - Mar 29, 2007 PipelineReview.com (press release),Enzon's specialized sales force markets Abelcet(R), Oncaspar(R), Adagen(R), and DepoCyt(R) in the United States. In addition, Enzon also receives royalties Enzon Enrolls First Patient in Phase 1 Study of Its HIF-1 Alpha ... - Mar 29, 2007 Business Wire (press release),Enzon's specialized sales force markets Abelcet®, Oncaspar®, Adagen®, and DepoCyt® in the United States. In addition, Enzon also receives royalties on sales Risa Bernstein, Agency Co-Founder, Returns to Flashpoint Medica - Jan 17, 2007 PharmaLive.com (press release),Enzon for Abelcet, an IV anti-fungal agent, Novogyne (Noven and Novartis) for Vivelle Dot (estradiol transdermal system), a hormone replacement patch, Enzon Announces CEO Cancer Gold Standard Accreditation - Jan 10, 2007 American Digital Networks (press release),Enzon's specialized sales force markets Abelcet(R), Oncaspar(R), Adagen(R), and Depocyt (R) in the United States. In addition, Enzon also receives royalties Enzon Announces CEO Cancer Gold Standard Accreditation - Jan 10, 2007 Business New Jersey (subscription),Enzon’s specialized sales force markets Abelcet®, Oncaspar®, Adagen®, and Depocyt ® in the United States. In addition, Enzon also receives royalties on Enzon Announces CEO Cancer Gold Standard Accreditation - Jan 10, 2007 Business Wire (press release),Enzon’s specialized sales force markets Abelcet ® , Oncaspar ® , Adagen ® , and Depocyt ® in the United States. In addition, Enzon also receives royalties Zacks Bull and Bear of the Day Highlights: Hittite Microwave ... - Jan 8, 2007 American Digital Networks (press release),Key product Abelcet sales continued to deteriorate for the third time in 2006. Although Royalty on PEG-Intron in the third quarter grew by 21% on a year : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |